CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2016—Horizon Discovery Group introduced its microinjection-ready Cas9 Accelerate Ribonucleoprotein. Cas9 Accelerate RNP maximizes gene-editing efficiency by enabling CRISPR reagents to sidestep the transcription and translation steps that traditional Cas9 plasmid and mRNA formats must complete before being activated, thereby maximizing gene-editing efficiency and lowering the risk of off-target effects.
Horizon Discovery, +44 (0) 1223 655 580